Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Different medications are often used in combination for the condition COPD (chronic
obstructive pulmonary disease). Some medicines act by opening the airways (bronchodilators)
and some act as anti-inflammatories (steroids). More recently an approach of using a
combination inhaler (containing a steroid and a long-acting bronchodilator) at the same time
as a long acting bronchodilator of a different group of medicines (anti-cholinergics
inhalers) has been used. This approach is sometimes called 'triple therapy'. Studies which
have looked at these combinations usually use only standard blowing tests (spirometry) to
test these medicines and focus on the effects of the medicines at their highest (peak)
levels. It is some ways more relevant to study these medicines towards to end of the dose
period (trough)- just before the next dose. This is when there is less medicine in the
system, and differences in drug effects are more obvious. There are also more detailed
breathing tests than spirometry which get a more detailed picture of the way the lungs
respond to bronchodilator medicines. The investigators have studied 'triple therapy' in COPD,
by measuring the effects at the end of the dosing interval (trough) using a range of detailed
respiratory tests.
Phase:
Phase 4
Details
Lead Sponsor:
Brian J Lipworth
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate Tiotropium Bromide